1 ongenital anomaly (multivariate RR 2.19, 95% CI 1.67-2.85);
we noted no association with increasing deprivation.
2 However,
we noted no changes in either group in invasive pneumococcal
3 However,
we noted no changes in rCBF and flux in presymptomatic carrie
4 We noted no clear evidence that the individual drugs had diff
5 We noted no clinically relevant differences between treatment
6 Upon challenge,
we noted no difference in colonization of the urine or kidney
7 We noted no difference in handgrip strength in ROMANA 1 (-1.1
8 We noted no difference in median recurrence-free survival bet
9 We noted no difference in progression-free survival between s
10 We noted no difference in survival between patients who were
11 We noted no differences at 12 months' follow-up between SDS a
12 We noted no differences in FEV1 slopes between the immediate
13 We noted no differences in parent or teacher ratings.
14 Additionally,
we noted no differences in physician-diagnosed post-stroke pn
15 We noted no differences in serious adverse events between gro
16 We noted no effect of patients starting memantine compared wi
17 We noted no effect on disease activity indices or other psych
18 in the EUC plus CAP group than in the EUC alone group, but
we noted no effect on mean daily alcohol consumed in the past
19 Additionally,
we noted no events of vaccine-associated paralysis.
20 We noted no evidence of an increased periprocedural risk by a
21 We noted no evidence of an increased risk of miscarriage or o
22 We noted no evidence of improvement in 30 day survival with L
23 We noted no evidence of selective benefit in patients aged 60
24 We noted no evidence that the effect of isoniazid preventive
25 We noted no grade 3 or 4 nor serious adverse events deemed to
26 We noted no heterogeneity for stroke or systemic embolic even
27 We noted no increase in mortality when toxigenic C difficile
28 We noted no increase in risk of adverse events with active tr
29 We noted no indication of disproportionate reporting of adver
30 We noted no long-term postoperative surgical complications.
31 We noted no overall additional toxic effects with cilengitide
32 We noted no relation between increased social spending and tu
33 We noted no severe hypoglycaemic episodes during the control
34 At 52 weeks,
we noted no significant difference between groups for disease
35 ns than the group without (IDR 1.39 [95% CI 1.07-1.79]) and
we noted no significant difference between groups in readmiss
36 187 (57%) experienced no discontinuities, and
we noted no significant difference between the CTO and contro
37 We noted no significant difference in clinical outcomes.
38 We noted no significant difference in intra-arterial treatmen
39 We noted no significant difference in overall survival betwee
40 After 12 months
we noted no significant difference in the change in left vent
41 In summary,
we noted no significant difference in the mean overall cost o
42 We noted no significant difference in the number of serious a
43 We noted no significant differences between statin users and
44 We noted no significant differences in lactate to N-acetyl as
45 We noted no significant differences in safety outcomes, apart
46 mprovements in dyspnoea and health-related quality of life;
we noted no significant differences in symptoms, health statu
47 was compared separately with placebo or active comparators,
we noted no significant differences.
48 We noted no statistically significant difference in overall r
49 We noted no substantial changes from baseline in vital signs,
50 INTERPRETATION:
We noted no survival benefit in men with metastatic castratio